We would love to hear your thoughts about our site and services, please take our survey here.
Saucisson, salami , frankfurters , you name it’s all on the heart attack list! Italy has a huge export market for this stuff. That’s what should be banned. Anywhere that feels threatened is going to get hostile to agrinomical economic. There is no logical reason to ban lab meat . The market will sort out what people want, not the Italians or red necks
Rhea extends the life of VME computers in which Cnc is involved in for 20 years. This a as a result off requests from the customers in the defence sector who are finding it hard to source components. Presumably they had enough requests to make it worth while. Whether it’s an obligation or a money spinner is hard to say. Perhaps not just out of the goodness of their hearts but also a security concern . Anyway a flurry of Pi activity first thing this morning. Fomo on something big?
The mice are all feeling pretty chipper I trust, until the grant runs out at Queensland. Not wishing to be a party pooper but the eternal student syndrome looms large. Still all about university research. Can’t see anything to get excited about until we get to clinical trials next year
There you go . Another great RNS completely ignored by the market. Roll on a buyout
Unfortunately it’s the Uk market which is screwed. Investment trusts in small caps in particular. The actual companies are brilliant and generally doing very well despite Brexit. When is this anomaly likely to change? Not for a good few years.
On the move on low volume. Does look a bit leaky. .9p paid. Imagine what this might do with some news of commerciality!
Have been away in Aus for while. I see there was a program to buy back £3 million of shares over six months from October to December. Someone doesnt appear to particularly good at maths, but the program appears not have been initiated at all. How much it could have stopped the slide I am not sure, but a realisation of continuing depression in the stock appears to have been foreseen possibly. A lot of talk in the press about liquidity issues in small caps and small cap funds. It does appear that the outflow from such is coming to a halt. So while the SP is over 50% below Nav, Perhaps they should think about buying back now. At break even, that would be a 100% gain, for a fund that used to trade at several multiples of its Nav.
Been a tricky year, but the new management sound impressive and hopefully will confirm a more positive outlook. Meanwhile ridiculously cheap
Anic net a whole £12.60 in the latest farce. Hope Jim will follow suit and exercise all his warrants with the millions he has stripped out in management fees. Presumably they expire this June unless they can extend them again.
Of course there will be resistance to lab meat. That was a given from the outset. This is a ‘disruptive’ business. Asia however will be very different . They have already invested heavily in lab meat. They do not have the luxury of choice because many Asian countries have to import 95 percent of their food. When it comes to the crunch it won’t be so much about freedom of choice but supply, demand and necessity. Still a long way to go and the big Texas ranches are all powerful., but Americas have a lot of poor people to feed. Uk is pretty lucky with wide choices Of farm shops and many alternatives . Wouldn’t touch any supermarket meat with a barge pole. Ed meats and processed meats are a recognised killer and very inefficient of producing protein
FTSE set to take a tumble’. Beginning to look and sound like an OAP. O dear , poor sir Elton’s taken a fall, and now the FTSE takes another tumble. Does it ever do anything else!
‘Liberation is set to be the first company in Anic’s portfolio to become cash generative’. I’m sure Jim says that about every company in the portfolio! Going to be a very long road that’s for sure
Dividend set for May/June on shareholder approval. Anyone going to object? Maybe then get further news on another special. I can’t seen the directors having emotions for takeovers, more ambitious to get the company sold and retire hopefully. Great job though
The risks are aplenty. Not just the need to commercialise before they run out of money but the many other competing research around the world. Their own research is very encouraging and two big investors recently have given a much needed vote of confidence. Unfortunately it is still very difficult to raise money in this sector. So those two seem pretty essential to helping this getting across the line.
Welcome the annual culling of revenues. Sheer slaughter as Stocko wittily jibed. There’s a thought, set a realistic target, and don’t waste time or money on anymore takeovers if you can’t make these ones pay their way. And don’t use ebitda every time to try and make it look less bad. Apart from that well done for ending up with a little cash ahead. How about a dividend? O I forgot it’s a growth company!
Thanks T-raider. Yes Lord Lee is a great patriot. Amongst many other things he used to be an advisor on defence to the government which I always felt was quite handy. Dont know what the last blip was about. Another fund manager throwing away client money probably.
Some thumping trades this morning. Two well over a million and two at half a million. I was wondering about the surplus cash. Ip dividend is not overly generous. Singer say there remains the opportunity for second special dividend on top of the maiden dividend. Be nice if they could manage both and the takeover!
SB. Indeed the hidden asset of 600 million tax credit as Chris Mills put it. Plus 22.5 million cash as of end of february. Valuation doesnt look stretched to me for 18 % growth compounding. The market is also growing possibly to 400 million in next decade. The improvement and cost of drugs also necessitates the accuracy of Feno for which Niox are currently in a field of their own.
Confirmed 23 year results from January. 18 percent revenue growth. 1p dividend confirmed for 2023 but no date set yet. Nearly 20 million cash balance plus whatever assets year (possibly another 5 million) . Lungfit approval in USA to add 10 million dollars over 3 years. Strong point made about the importance of the uptake of FeNo testing with better and more expensive drugs becoming available. Asset value just over 80 million. All in all the stock set to become very undervalued if progress only continues at this pace but of course likely to accelerate further with development of home kit and the larger updated version of current diagnostic machine. Still early days for a bid maybe, but depends how much quicker a larger company could place and develop their products. I would imagine the current sp would be largely supported by todays update, but who can tell in this mad market!
Apart from results being overdue. The review is over due. The dividend was reinstated in feb payed out a couple of days ago? With an offer to reinvest dividends . Doesn’t sound like a company in trouble it’s the markets in general that are in trouble over reacting to every tiny bit of gossip/news item or no news . I would imagine the outcome of the late review would have some bearing on an update date. As previously mentioned jobsworth stringing it out for a ridiculous length of time while god knows what skullduggery is being perpetrated all over the markets completely un hindered by anything approaching the semblance of a regulator